Übersichtsarbeit

,
Filler auf dem Markt

Fillers on the market

Keywords | Summary | Correspondence | Literature

Keywords

, , , ,

Schlüsselworte

, , , ,

Summary

The improvement of skin appearance, by restoring lost contours and volumes and treating muscular relaxation, has long been the principal goal of facial aesthetic medicine. The use of injectable materials within soft tissues has greatly increased in recent years. Hyaluronic acid fillers represent a classic example. These fillers vary widely in physical and chemical characteristics and in their correct positioning in the dermis, influencing the desired aesthetic result. In several of these compounds has also been added, within the pre-filled syringe, some anesthetic (lidocaine) to reduce the discomfort connected to the injection technique. Other fillers commonly used are made of calciumhydroxyapatite and poly-L-lactic acid. They have a long lasting effect and are highly biocompatible. In general, the ideal filler should be biocompatible, should not cause any inflammation or granuloma formation and should be durable over time. Nowadays there is no filler that encompasses all of these features, in fact all the compounds above mentioned may be responsible for the onset of adverse events. Therefore, the knowledge of the physico-chemical characteristics of the products can help the dermatologist, along with his / her personal experience, choosing the most suitable filler to be injected in order to achieve the result desired by the patient, reducing downtime and related morbidity.

Zusammenfassung

Die Verbesserung des Hautbildes durch Wiederherstellung verlorener Konturen und Volumina, sowie die Behandlung von muskulärer Relaxation,ist schon immer das oberste Ziel der ästhetischen Medizin des Gesichts gewesen. Der Einsatz injizierbarer Materialien innerhalb des Weichgewebes, hat in den letzten Jahren stark zugenommen. Hyaluronsäure-Filler repräsentieren ein klassisches Beispiel. Diese Filler unterscheiden sich durch ihre verschiedenen physischen und chemischen Charakteristika und in deren richtigen Positionierung in der Dermis, um das gewünschte ästhetische Ergebnis zu erzielen. Einigen Präparaten wird auch Lidocain beigemengt, um die Schmerzen der Injektionstechnik zu reduzieren. Andere angewandte Filler werden aus CalciumHydroxyapatit und Poly-L-Milchsäure (PLLA) hergestellt. Diese Filler haben einen lang anhaltenden Effekt und sind höchst biokompatibel. Allgemein gesagt, sollte der ideale Filler biokompatibel sein, sollte keine Inflammation oder Granulome verursachen und er sollte dauerhaft sein. Bis heute gibt es keinen Filler, der alle diese Eigenschaften umfasst. Tatsache ist, dass alle oben genannten Wirkstoffe unerwünschte Nebenwirkungen verursachen können. Deshalb kann das Wissen über die physischen und chemischen Eigenschaften der Produkte, dem Arzt, zusammen mit seiner Erfahrung, helfen, den passenden Filler auszuwählen, um das vom Patienten gewünschte Ergebnis zu erzielen und um die Ausfallzeit und andere Risiken zu minimieren.

Leider haben Sie sich nicht eingeloggt, um den Beitrag lesen zu können. Bitte loggen Sie sich ein oder beantragen Sie Ihre Zugangsberechtigung. Vielen Dank. Weitere Informationen finden Sie hier>

Korrespondenz-Adresse

Ilaria Ghersetich, MD
Division of Clinical, Preventive and Oncologic Dermatology
Dept. of Critical Care Medicine and Surgery
University of Florence
Ospedale P. Palagi
Viale Michelangelo 41
I-50100 Firenze
ilariaghersetich@yahoo.it

Conflict of Interests

Author

Literatur

1. Tezel A, Fredrickson GH (2008). The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 10: 35-42.
2. American Society of Plastic Surgeons (2006) Injectable fillers: Improving skin texture. Arlington Heights, IL: American Society of Plastic Surgeons; 2006. Accessed June 22, 2006. URL: http://www.plasticsurgery.org/public_ education/procedures/InjectableFillers.cfm
3. Donofrio L, Weinkle S (2006) The third dimension in facial rejuvenation: A review. J Cosmet Dermatol 5: 277-283.
4. Carruthers J, Cohen SR, Joseph JH, et al. (2009) The science and art of dermal fillers for soft-tissue augmentation. J Drugs Dermatol 8: 335-350.
5. Wollina U, Goldman A (2011) Hyaluronic acid dermal fillers: Safety and efficacy for the treatment of wrinkles, aging skin, body sculpturing and medical conditions. Clin Med Rev Ther 3: 107-121.
6. Goldman A, Wollina U (2010) Facial rejuvenation for middle-aged women: A combined approach with minimally invasive procedures. Clin Interv Aging 5: 293-299.
7. Wollina U, Goldman A (2013) Dermal fillers: Facts and controversies. Clinic Dermatol 31: 731–736.
8. Rivkin A (2009) New fillers under consideration: what is the future of injectable aesthetics? Facial Plast Surg 25: 120-123.
9. Pickett A (2011) Serious issues relating to counterfeit dermal fillers available from Internet sources. J Am Acad Dermatol 65: 642-643.
10. Glaich AS, Cohen JL, Goldberg LH (2006) Injection necrosis of the glabella: Protocol for prevention and treatment after use of dermal fillers. Dermatol Surg 32: 276-281.
11. Rohrich RJ, Pessa JE (2007) The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg 119: 2219-2227.
12. Carruthers J, Glogau R, Blitzer A (2008) Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies: consensus recommendations. Plast Reconstr Surg 121: 5–30.
13. Berbos ZJ, Lipham WJ (2010) Update on botulinum toxin and dermal fillers. Curr Opin Ophthalmol 21: 387-395.
14. Greco TM, Antunes MB, Yellin SA. (2012) Injectable fillers for volume replacement in the aging face. Facial Plast Surg 28: 8-20.
15. Prendergast PM (2012) Anatomy of the Face and Neck. Cosmetic Surgery, Springer-Verlag Berlin Heidelberg 29-45.
16. Mendelson B, Hartley W, Scott M et al. (2007) Age-related changes of the orbit and midcheek and the implications for facial rejuvenation. Aesthetic Plast Surg 31: 419–423.
17. Greco TM, Elenitsas R (2010) Localization and histological characterization of injected hyaluronic acid in excised nasolabial fold tissue. J Drugs Dermatol 9: 399–404.
18. Klein AW (2006) Techniques for soft tissue augmentation: an ‘a to z’. Am J Clin Dermatol 7: 107–120.
19. Park KY, Kim HK, Kim BJ (2013) Comparative study of hyaluronic acid fillers by in vitro and in vivo testing. J Eur Acad Dermatol Venereol. In press. 20. Hilinski JM, Cohen SR (2009) Soft tissue augmentation with ArteFill. Facial Plast Surg 25: 114–119.
21. Nast A, Reytan N, Hartmann V et al. (2011) Efficacy and durability of two hyaluronic acid-based fillers in the correction of nasolabial folds: results of a prospective, randomized, double-blind, actively controlled clinical pilot study. Dermatol Surg 37: 768-775.
22. Arlette JP, Trotter MJ (2008) .Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg 1: 56-62.
23. Weiss R, Bank D, Brandt F (2010) Randomized, Double-Blind, Split-Face Study of Small-Gel-Particle Hyaluronic Acid with and without Lidocaine During Correction of Nasolabial Folds. Dermatol Surg 36: 750–759. 24. Levy PM, De Boulle K, Raspaldo H (2009) Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone. Dermatol Surg 1: 332-336.
25. Callan P, Goodman GJ, Carlisle I et al. (2013) Efficacy and safety of a hyaluronic acid filler in subjects treated for correction of midface volume deficiency: a 24 month study. Clin Cosmet Investig Dermatol 6: 81-89. 26. Raspaldo H. (2008) Volumizing effect of a new hyaluronic acid subdermal facial filler: a retrospective analysis based on 102 cases. J Cosmet Laser Ther 10: 134-142.
27. Eccleston D, Murphy DK (2012) Juvéderm(®) Volbella™ in the perioral area: a 12-month prospective, multicenter, open-label study. Clin Cosmet Investig Dermatol 5: 167-172.
28. Hedén P, Sellman G, von Wachenfeldt M et al. (2009) Body shaping and volume restoration: the role of hyaluronic acid. Aesthetic Plast Surg 33: 274-282.
29. Sadick NS, Anderson D, Werschler WP (2008) Addressing volume loss in hand rejuvenation: a report of clinical experience. J Cosmet Laser Ther 10: 237-241.
30. Cohen JL. (2008) Understanding, avoiding, and managing dermal filler complications. Dermatol Surg 4: 92–99.
31. Park TH, Seo SW, Kim JK et al. (2011) Clinical experience with hyaluronic acid-filler complications. J Plast Reconstr Aesthet Surg 64: 892-896.
32. Kim DW, Yoon ES, Ji YH et al. (2011) Vascular complications of hyaluronic acid fillers and the role of hyaluronidase in management. J Plast Reconstr Aesthet Surg 64: 1590-1595.
33. Yocum RC, Kennard D, Heiner LS (2007) Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs 30: 293-299.
34. Busso M, Applebaum D (2007) Hand augmentation with Radiesse (Calcium hydroxylapatite). Dermatol Ther 20: 385-387.
35. Marmur ES, Al Quran H, De Sa Earp AP et al. (2009) A five-patient satisfaction pilot study of calcium hydroxylapatite injection for treatment of aging hands. Dermatol Surg 35: 1978-1984.
36. Fabi SG, Goldman MP. (2012) Hand rejuvenation: a review and our experience. Dermatol Surg 38: 1112-1127.
37. Van Dam D, Van Der Lei B, Cromheecke M (2009) Statements on the safety of permanent soft tissue fillers in Europe. Aesthetic Plast Surg 33: 479-481.
38. Borelli C, Kunte C,Weisenseel P et al. (2005) Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy inHIV-infected patients. Skin Pharmacol Physiol 18: 273–278.
39. Rohrich RJ, Sullivan D (2011) So you want to be like Leonardo da Vinci or Michelangelo? Which one are you? Plast Reconstr Surg 128: 1309-1311.
40. Narins RS, Donofrio L (2010) Updates on fillers. Dermatol Surg 36: 729.

Ausgabe